3. Publikationsliste. Prim. Univ.-Prof. Dr. Andreas Petzer. Abteilung Interne I: Internistische Hämatologie, Onkologie und Gastroenterologie

Size: px
Start display at page:

Download "3. Publikationsliste. Prim. Univ.-Prof. Dr. Andreas Petzer. Abteilung Interne I: Internistische Hämatologie, Onkologie und Gastroenterologie"

Transcription

1 3. Publikationsliste Prim. Univ.-Prof. Dr. Andreas Petzer Abteilung Interne I: Internistische Hämatologie, Onkologie und Gastroenterologie 1

2 I. Originalarbeiten Vor der Habilitation: 1. Schulz T. F., Helmberg A., Hosp M., Petzer A., Föger B. and Dierich M.P. (1985) Enzyme-linked immunoassay to monitor the purification of, and screen for monoclonal antibodies against, C3b receptor. Complement, 2, Dierich M. P., Erdei A., Huemer H., Petzer A., Stauder R., Schulz T. F. and Gergely J. (1987) Involvement of complement in B-cell, T-cell and monocyte/macrophage activation. Immunology Letters, 14: Petzer A. L., Schulz T. F., Stauder R., Eigentler A., Myones B. L. and Dierich M.P.(1988) Structural and functional analysis of CR2/EBV receptor by means of monoclonal antibodies and limited tryptic digestion. Immunology, 63: Pernegger G., Schulz T. F., Hosp M., Myones B. L., Petzer A. L., Eigentler A., Böck G., Wick G. and Dierich M. P.(1988) Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor. Immunology, 65: Eigentler A., Schulz T.F., Larcher C., Breitwieser E., Myones B.L., Petzer A.L.and Dierich M.P. (1989) C3bi-binding protein on Candida albicans: Its temperature-dependent expression and its relationship to human complement receptor typ 3. Infection & Immunity, 57/2:

3 6. Petzer A. L., Bilgeri R., Zilian U., Haun M., Geisen F.H., Pragnell I., Braunsteiner H. and Konwalinka G. (1991) The Inhibitory Effect of 2-Chlorodeoxyadenosine on Granulocytic, Erythroid and T-lymphocytic Colony Growth. Blood, Vol 78: No Bilgeri R., Petzer A.L., Zilian U., Geisen F.H., Schirmer M., Haun M., Braunsteiner H, Konwalinka G. (1993) Effect of deoxycytidine on 2-chlorodeoxyadenosine-mediated growth inhibition of normal human erythroid and myeloid progenitor cells.exp. Hematol., 21: Holyoake T.L., Freshney M.G., Konwalinka G., Haun M., Petzer A., Fitzsimons E., Lucie N.P., Wright E.G., Pragnell I.B. (1993) Mixed colony formation in vitro by the heterogenous compartment of multipotential progenitors in human bone marrow. Leukemia, Vol 7, No 2: Huemer H.P., Larcher C., Prodinger W.M., Petzer A.L., Mitterer M., Falser N. (1993) Determination of soluble CD21 as a parameter of B cell activation. Clin. Exp. Immunol., 93: Petzer A.L., Geisen F., Bilgeri R., Zilian U., Haun M., Herold M., Konwalinka G., Braunsteiner H. (1995) Growth-inhibitory effect of 2-chlorodeoxyadenosine (2-CdA) on myeloid CFU-GM progenitors in normal human long-term bone marrow cultures and its compensation by G-CSF or IL-3. Exp. Hematol., 23:

4 11. Konwalinka G., Schirmer M., Hilbe W., Fend F., Geisen F., Knoblechner A., Petzer A., Thaler J. (1995) Minimal residual disease in hairy-cell leukemia after treatment with 2-Chlorodeoxyadenosine. Blood Cells, 21(14) July 31: Petzer A.L., Hogge D.E., Lansdorp P.M., Reid D.S., Eaves C.J. (1996) Self-renewal of primitive human hematopoietic cells (LTC- IC) in vitro and their expansion in defined media. Proc. Natl. Acad. Sci. USA, Vol.93, Feb. 1996: Petzer A.L., Zandstra P.W., Piret J.M, Eaves C.J. (1996) Differential cytokine effects on primitive (CD34 + CD38 - ) human hematopoietic cells: Novel responses to Flt3-Ligand and thrombopoietin. J. Exp. Med., Vol.183, June 1996: Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett M, Eaves AC. (1996) Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood, Vol.88, Sept. 1996: Maguer-Satta V, Petzer AL, Eaves AC, Eaves CJ (1996) BCR- ABL expression in different subpopulations of functionally characterized Ph + CD34 + cells from patients with chronic myeloid leukemia. Blood, Vol.88, Sept 1996:

5 Nach der Habilitation: 16. Zandstra P.W., Petzer A.L., Eaves C.J., Piret J.M, (1997) Cellular determinants affecting the rate of cytokine depletion in cultures of human hematopoietic cells. Biotechnology & Bioengineering, Vol.54, No.1, April 5, Hogge D, Fanning S, Bockhold K, Petzer A.L., Lambie K, Lansdorp P, Eaves AC, Eaves C.J. (1997) Quantitation and characterization of human megakaryocyte colony-forming cells using a standardized serum-free agarose assay. Br. J. Haematology, Vol. 96: Zandstra P.W., Conneally E, Petzer A.L., Piret J.M, Eaves C.J.(1997) Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc. Natl. Acad. Sci. USA, Vol. 94, April 1997: Petzer AL, Eaves CJ, Barnett M, Eaves AC. (1997) Selective expansion of primitive normal hematopoietic cells in cytokinesupplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood, Vol 90, July 1997: Gunsilius E, Petzer A, Gastl G.(1997) Hochdosistherapie mit Transplantation autologer peripherer hämatopoetischer Stammzellen (High dose therapy with autologous peripheral stem cell transplantation) I. Grundlagen und klinische Entwicklung (I. Basic principles and clinical development). Acta Medica Austriaca, Vol 24(3):

6 21. Gunsilius E, Petzer A, Gastl G.(1997) Hochdosistherapie mit Transplantation autologer peripherer hämatopoetischer Stammzellen (High dose therapy with autologous peripheral stem cell transplantation) II. Indikationen und klinische Ergebnisse (II. Indications and clinivcal results). Acta Medica Austriaca, Vol 24(3): Conneally E, Cashman J, Petzer A, Eaves C (1997) Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid mice. PNAS 1997, Sept. 2, Vol.94(18): Eaves C, Miller C, Cashman J, Conneally E, Petzer A, Zandstra P, Eaves A. (1997). Hematopoietic Stem Cells: Inferences from In Vivo Assays. Stem Cells 1997, Vol.15 (suppl 1): Eaves C, Zandstra P, Conneally E, Miller C, Cashman J, Petzer A, Piret J. (1998). Changes in the cytokine regulation of stem cell self- renewal during ontogeny. Stem Cells 1998, 16 (suppl 1): Eaves AC, Barnett MJ, Ponchio L, Cashman JD, Petzer AL, Eaves CJ. (1998). Differences between normal and CML stem cells Potential targets for clinical exploitation. Stem Cells 1998, 16 (suppl 1):

7 26. Petzer AL, Conneally E, Zandstra PW, Cashman JD, Gastl G, Eaves AC, Eaves CJ. (1998). In vitro expansion of primitive progenitors (LTC-IC, CRU) under defined culture conditions. Bone Marrow Transplantation, 22, Suppl.3: S Gunsilius E, Lass-Flörl C, Mur E, Gabl C, Gastl G, Petzer AL. (1999) Aspergillus arthritis in acute lymphoblastic leukemia. Ann. Hematol., 78: Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, Gastl G. (2000). Thrombocytes are the major source for soluble vascular endothelial growth factor in the peripheral blood. Oncology, 58: Petzer AL, Gunsilius E, Zech N, Clausen J, Hoflehner E, Nussbaumer W, Gastl G. (2000). Evaluation of optimal survival of primitive progenitor cells (LTC-IC) from PBPC apheresis products after overnight storage. Bone Marrow Transplantation, 25: Gunsilius E*, Duba H-Ch*, Petzer AL*, Kähler CM*, Grünewald K, Stockhammer G, Gabl Ch, Dirnhofer S, Clausen J, Gastl G. (2000) Evidence from a leukaemia model for the maintenance of the blood vascular endothelium by bone-marrow derived endothelial cells. Lancet, 355: , mit Editorial; *equal contribution 31. Gunsilius E, Lass-Flörl C, Kähler C, Gastl G and Petzer A (2001). Candida ciferrii, another fluconazole-resistant yeast causing systemic mycosis in immunocompromised patients. Ann. Hematol; 80(3):

8 32. Clausen J, Petzer AL, Vergeiner B, Enk M, Gastl G and Gunsilius E. (2001). Optimal Timing for the Collection and In Vitro Expansion of Cytotoxic CD56 + Lymphocytes from Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation. Journal of Hematotherapy and Stem Cell Research; 10 (4): Gunsilius E, Gastl G, Petzer AL (2001). Hematopoietic stem cells. Biomed Pharmacother; 55 (4) : Lass-Flörl C, Aigner J, Gunsilius E, Petzer A, Nachbaur D, Gastl G, Einsele H, Löffler J, Dierich MP, Würzner R (2001). Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. British Journal of Haematology; 113 (1), Petzer AL, Hochenburger E, Haun M, Duba HC, Grünewald K, Hoflehner E, Sill H, Linkesch W, Gastl G, Gunsilius E (2002). High-dose hydroxyurea plus G-CSF mobilize BCR-ABL- negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration. J Hematother Stem Cell Res; 11(2): Petzer AL, Speth HG, Hoflehner E, Clausen J, Nachbaur D, Gastl G, Gunsilius E (2002). Breaking the rules? X-ray examination of haematopoietic stem cell grafts at international airports. Blood; 99 (12): Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, Schneller F, Grünewald K, Poewe W, Gastl G (2002). Low concentraions of STI571 in the cerebrospinal fluid: a case report. Br J Hematol; 117(3):

9 38. Keil F, Elahi F, Greinix HT, Fritsch G, Louda N, Petzer AL, Prinz E, Wagner T, Kalhs P, Lechner K, Geissler K (2002). Ex vivo expansion of long-term culture initiaing marrow cells by IL-10, SCF, and IL-3. Transfusion; 42(5): Gunsilius E, Tschmelitsch J, Eberwein M, Schwelberger H, Spizzo G, Kahler CM, Stockhammer G, Lang A, Petzer AL, Gastl G. (2002). In vivo release of vascular endothelial growth factor from colorectal carcinomas. Oncology; 62(4): Clausen J, Vergeiner B, Enk M, Petzer AL, Gastl G, Gunsilius E (2003). Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiol.; 207: Lass-Flörl C, Gunsilius E, Gastl G, Englisch M, Koch G, Ulmer H, Dierich MP, Petzer A (2003). Fungal colonization in neutropenic patients: a randomized, double-blind study comparing itraconazole solution and amphotericin B solution. Annals of Hematology; 82: Zech NH, Gunsilius E, Clausen J, Hoflehner E, Hoelzler K, Gastl G, Petzer AL (2003). Expansion of Mobilized Peripheral Blood Progenitor Cells under Defined Culture Conditions using CD34+CD71-CD45- Cells as Starting Population. J of Hematotherapy and Stem Cell Research; 12: Petzer A, Gunsilius G (2003). Hematopoietic Stem Cells in Chronic Myeloid Leukemia. Archives of Medical Research, Vol 34, Issue 6: (Review Article) 9

10 44. Lass-Flörl C, Gunsilius E, Gastl G, Bonatti H, Freund MC, Gschwendtner A, Kropshofer G, Dierich MP and Petzer A. (2004). Diagnosing invasive asperigillosis during antifungal therapy by PCR analysis of blood samples. Journal of Clinical Microbiology; 42 (9): Clausen J, Enk M, Vergeiner B,EisendleK, Glassl H, Petzer AL,Gastl G, Gunsilius E. (2004) Suppression of Natural Killer Cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes. Biol Blood Marrow Transplant 10(10): Eisterer W, Jiang X,Christ O, Glimm H, Lee KH, Pang E, Lambie K, Shaw G, Holyoake TL, Petzer AL, Auewarakul Ch, Barnett MJ, Eaves CJ, Eaves AC (2004). Different subsets of primary Chronic Myeloid Leukemia Stem Cells engraft immnodeficient mice and produce a model of the human disease. Leukemia 47. Cornelia Lass-Flörl, Karharina Griff, Astrid Mayr, Andreas Petzer, Günter Gastl, Hugo Bonatti, Martin Freund, Gabriele Kropshofer, Manfred P. Dierich and David Nachbaur (2005). Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. British Journal of Haematology; 131: RF Schlenk, U Germing, F Hartmann, A Glasmacher, JT Fischer, F del Valle y Fuentes, K Götze, H Pralle, C Nerl, H Salwender, W Grimminger, A Petzer, M Hensel, A Benner, L Zick, K Döhner, S Fröhling and H Döhner, for the AML Studiy Group (AMLSG) (2005). High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia; 9: J. Clausen, D. Wolf, A.L. Petzer, E. Gunsilius, P. Schumacher, B. Kircher, G. Gastl and D. Nachbaur (2007). Impact of natural killer cell dose and donor 10

11 killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Britisch Society for Immunology, Clinical and Experimental Immunology; 148/3: Günther F. Körmöczi, Eva-Maria Dauber, Oskar A. Haas, Gerhard Fritsch, Markus Raderer, Christoph Buchta, Andreas L. Petzer, Diether Schönitzer, Wolfgang R. Mayr, Christoph Gassner (2007). Mosaicism due to myeloid lineage-restricted loss of heterozygosity as cause of spontaneous Rh phenotype splitting. Blood; 110/6: Jutta Auberger, Johannes Clausen, Martin Erdel, Eberhard Gunsilius, Andreas Petzer, Günther Gastl and David Nachbaur (2007). Fludarabine/intermediatedose cytarabine with or without allogeneic hematopoietic stem cell transplantation in poor-risk leukemia: a single center experience. Int J Hematol; 87(4): Kircher Brigitte, Schumacher Petra, Petzer Andreas, Hoflehner Elisabeth, Nachbaur David, Gastl Günther (2007). Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Eur J Haematol; Epub ahead of print. 53. Ernst Rechberger, Gerald Webersinke, Andreas Petzer (2008). Chronische Myeloproliferative Erkrankungen (CMPE). Wiener Klinische Wochenschrift; 01: Peter Valent, Thomas Lion, Dominik Wolf, Christian Sillaber, Hermine Agis, Andreas Petzer, Alois Lang, Peter Kahls, Dietmar Geissler, Richard Greil, Werner Linkesch, Sonja Burgstaller, Josef Thaler, Günther Gastl (2008) Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wiener Klinische Wochenschrift; Vol. 120, 21:

12 55. Josef Hammer, Christine Track, Dietmar H. Seewald, Kurt J. Spiegl, Johannes Feichtinger, Andreas L. Petzer, Werner Langsteger, Sabine Pöstlberger, Elsisabeth Bräutigam (2009) Local Relapse fter Breast-Conserving Surgery and Radiotherapy Effects on Survival Parameters. Strahlentherapie und Onkologie; 7: Andreas L. Petzer, Dominik Wolf, Dominic Fong, Thomas Lion Irina Dyagil, Zvenyslava Masliak, Andrija Bogdanovic, Laimonas Griskevicius, Sandra Lejniece, Stefan Goranov, Liana Gercheva, Aleksandar Stojanovic, Dontcho Peytchev, Nikolay Tzvetkov, Rasa Griniute, Radka Oucheva, Hanno Ulmer, Marthin Kwakkelstein, Francesca Rancati, Guenther Gastl (2010). High dose imatinib improves cytogenetic and molecular remissions in pretreated Ph+/BCR-ABL+ CML chronic phase patients: First results from a randomized CELSG CML 11 Phase III ISTAHIT Study. Haematologica; 95(6): R. Schlenk, K. Döhner, S. Mack, M. Stoppel, F. Király, K. Götze, F. Hartmann, H.A. Heinz, E. Koller, A.L. Petzer, W. Grimminger, G. Kobbe, A. Glasmacher, H. Salwender, H. Kirchen, D. Haase, S. Kremers, A Matzdorff, A. Benner, H. Döhner (2010) Prospective evaluation of allogeneic hematopoietic stem cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. JCO; 28: K. Kurz, K. Garimorth, M. Joannidis, D. Fuchs, A.L. Petzer, G. Weiss (2010) Altered immune responses during septicaemia in patients suffering from haematological malignancies eingereicht! II. Letters to the Editor, Editorials, Kommentare Vor der Hamilitation: 1. Hengster P., Kofler H., Eigentler A., Larcher C., Petzer A., Schulz T., Fritsch P. and Dierich M.P. (1986) Efficacy of Pasteur Hepatitis B vaccine in medical students. Letter to Lancet, Dec.6,

13 2. Wiedermann C.J., Bilgeri R., Petzer A., Gattringer C., Geissler D., Konwalinka G. (1989) Multipotent stem cell origin of myelodysplastic syndromes. Letter to Blood, Vol 73, Nach der Habilitation: 3. Gunsilius E, Petzer AL, Gastl G. (1999) Space flight and growth factors. Letter to Lancet, May 1, 353 (9163): Gunsilius E, Petzer AL, Gastl G. (1999) Vascular endothelial growth factor platelet counts and renal cancer. Letter to Lancet, June 26, 353 (9171): Gunsilius E, Petzer AL, Gastl G. (1999) Correspondence re: P. Salven et al., leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin. Cancer Res., 5: Gunsilius E, Petzer AL, Gastl G. (2000) Angiogenic growth factors and endostatin in non-hodgkin's lymphoma. Br J Haematol; 108 (3): Gunsilius E, Duba HC, Petzer AL, Kahler CM, Gastl GA (2000). Reply (Angiogenesis in chronic meylogenous leukemia). Lancet; 356 (Issue 9284): Gunsilius E, Tschmelitsch J, Petzer AL (2001). Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer; clinical evidence of platelet scavenging? Clin Cancer Res.; 7 (2): Gunsilius E, Petzer AL, Stockhammer G, Kähler CM, Gastl G (2001). Serial Measurement of Vascular Endothelial Growth Factor and Transforming Growth Factor-ss1 in Serumof Patients with Acute Ischemic Stroke. Stroke; 32(1):

14 10. Gunsilius E, Duba HC, Petzer AL, Kähler CM, Gastl GA (2001). Contribution of Endothelial Cells of Hematopoietic Origin to Blood Vessel Formation. Circ Res; 88(1). 11. Gunsilius E, Petzer AL, Duba HC, Kähler CM, Gastl G (2001). Circulating endothelial cells after transplantation. Lancet; 357 (9266): Gunsilius E, Petzer AL, Gastl GA (2002). Blood levels of vascular endothelial growth factor in obstructive sleep apnea-hypopnea syndrome. Blood; 99(1):

15 III. Bücher, Buchbeiträge, etc. Vor der Habilitation: 1. Stauder R, Schulz T.F., Petzer A., Eigentler A. and Dierich M.P. (1987) Identification of antibodies to leucocyte membrane-associated C3-binding proteins. Leukocyte Typing III - White Cell Differentiation Antigens (McMichael, A.J., Ed.) Oxford University Press, Konwalinka G., Wiedermann C.J., Petzer A., Grünewald K., Breier C., Geissler D. (1988) Stimulation of early and late erythropoietic progenitor cells by insulin: evidence for different mechanisms. Molecular Biology of Hematopoiesis, ed. by Mehdi Tavassoli, Esmail D. Zanjani, Joaon L. Ascensao, Nader G. Abraham and Alan S. Levine (Plenum Publishing Corporation, 1988), pp Petzer A. L., Bilgeri R., Geisen F.H., Zilian U., Haun M., Braunsteiner H. and Konwalinka G. (1992) Inhibitory activity of 2- chlorodeoxyadenosine and antagonization by deoxyctidine: Investigations on human normal and chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GM, BFU-E, CFU-E). Molecular Biology of Haematopoiesis 1992 Vol 2, Intercept Ltd., ed. by N. G. Abraham et. al., 60, , Buchartikel 4. Konwalinka G., Helson C., Bravermann S., Petzer A, Bilgeri R., Zilian U., Geisen F., Mittelman A., Abraham N., Ahmed T., Helson L. (1992) Growth inhibitory properties of 2-chlorodeoxyadenosine (2-CdA) against human nervous system tumors. Molecular Biology of Haematopoiesis 1992 Vol 2, Intercept Ltd., ed. by N. G. Abraham et. al., 55, , Buchartikel 15

16 IV. Abstracts Vor der Habilitation: 1. Schulz T.F., Petzer A., Stauder R., Eigentler A. and Dierich M.P. (1986) Expression of CR2(C3d/EBV-receptor) on HTLV-1- transformed human T-cells. Immunobiol., 173, Schulz T.F., Pernegger G., Petzer A., Eigentler A., Myones B.L., and Dierich M.P. (1987) Growth control of B-lymphoblastoid cells by CR2: Stimulation or Inhibition is dependent, upon the individual or simultanous engagement of suitable CR2 epitopes. Complement 4, Pernegger G., Schulz T.F., Myones B.L., Eigentler A., Petzer A. and Dierich M.P. (1987) Stimulation of the C3d/EBV-receptor, CR2, results in the enhanced growth of a Burkitt-lymphoma cell line. Immunobiology, Vol. 175, 4, 366; L Petzer A., Schulz T. F., Möst J., Hosp M., Topar G., Konwalinka G. and Dierich M. P. (1988) Analysis of CR2 Expression on Raji cells stimulated by anti-cr2 monoclonal antibodies in serum free medium. Blut,Vol. 57, 4, 187; Konwalinka G., Wiedermann C. W., Petzer A., Grünewald K., Breier Ch., Patsch J., Geissler D. and Braunsteiner H. (1988) Release of burst promoting activity from accessory cells by insulin: measurement in a serum-free system. Blut, Vol. 57, 4, 185, Geissler D., Greil R., Stauder R. Petzer A., Schulz T., Dierich M. P., Huber H. and Konwalinka G. (1988) Involvement of an 85 kd T- cell activation antigen in the modulation of committed hematopoetic progenitor cells in vitro. Blut, Vol. 57, 4, 254,

17 7. Bilgeri R., Geissler D., Freshney M., Petzer A., Wiedermann C.W., Zwierzina H., Pragnell I., Konalinka G. and Braunsteiner H. (1988) Evaluation of T-lymphocytic and pluripotent stem cell cloning efficiency in patients with myelodysplatic syndrome. Blut, Vol. 57, 4, 255, Hosp M., Topar G., Möst J., Schulz T.F., Petzer A.L. and Dierich M.P. (1988) The synthesis and expression of CR2 on Raji cells is enhanced by a factor in human serum. Immunobiol., Vol. 178, Pernegger G., Schulz T.F., Petzer A., Eigentler A., Myones B.L. and Dierich M.P. (1988) Growth control of cultured B- lymphoblastoid cells by C3d/EBV-receptor (CR2) under serum free conditions. Zbl. Bakt. Hyg. A 268, Petzer A.L., Bilgeri R., Zilian U., Haun M., Geisen F., Konwalinka G. (1991) 2-Chlorodeoxyadenosine inhibits colony growth of myeloid progenitor cells (CFU-e, BFU-e, CFU-gm) in vitro. Int.J.Cell Cl., Vol. 9, No 4, Petzer A.L., Bilgeri R., Zilian U., Haun M., Konwalinka G. (1991) The effect of 2-Chlorodeoxyadenosine on granulocytic, erythroid and T-lymphocytic colony growth. Schweiz.med. Wschr., 121, Suppl Petzer A.L., Bilgeri R., Zilian U., Geisen F., Konwalinka G.(1991) 2-Chlorodeoxyadenosine (CdA): Its inhibitory effect on granulocytic erythroid and T-lymphocytic colony growth.onkologie, 14, suppl. 2,

18 13. Bilgeri R., Petzer A.L., Zilian U., Haun M., Geisen F., Konwalinka G. (1991) CdA-mediated growth inhibition of normal human myeloid progenitor cells can partially be anatagonized by deoxycytidine. Onkologie, 14, suppl. 2, Bilgeri R., Petzer A.L., Zilian U., Haun M., Geisen F., Konwalinka G. (1991) Effect of deoxycytidine on CdA-mediated growth inhibition of normal human myeloid progenitor cells. Int.J.Cell Cl., Vol. 9, No 4, Bilgeri R., Petzer A.L., Zilian U., Geisen F., Haun M., Konwalinka G. (1992) Protective effect of deoxycytidine on 2-CdA treated human bone marrow cultures. Ann. Hematol., Vol. 65, suppl., Petzer A.L., Bilgeri R., Zilian U., Geisen F., Haun M., Herold M, Konwalinka G. (1992) 2-Chloro-2 -deoxyadenosine (CdA) affects myeloid progenitors but not stromal cells in normal human long-term bone marrow cultures (LTBMCs). Ann. Hematol., Vol. 65, suppl., Bilgeri R., Petzer A.L., Zilian U., Geisen F., Haun M., Konwalinka G. (1992) Protective effect of deoxycytidine on 2-CdA treated human bone marrow cultures. Ann. Hematol., Vol. 65, suppl., Petzer A.L., Bilgeri R., Zilian U., Geisen F., Haun M., Herold M, Konwalinka G. (1992) Dose dependent growth-inhibitory effect of 2- Chloro-2 -deoxyadenosine (CdA) in normal human long-term bone marrow cultures (LTBMCs). Ann. Hematol., Vol. 65, suppl.,

19 19. Konwalinka G., Petzer A., Geisen F.H., Schirmer M., Zilian U., Haun M., Braunsteiner H. (1993) A differential sensitivity to 2- chlorodeoxyadenosine (2-CdA) between normal and chronic myeloid leukemic bone marrow erythroid and myeloid progenitor cells. Exp. Hematol.Vol. 21, 1072 (227). 20. Petzer A.L., Geisen F.H., Bilgeri R., Zilian U., Haun M., Herold M, Braunsteiner H., Konwalinka G. (1993) Growth inhibitory effect of 2-chloro-2'-deoxyadenosine (CdA) on myeloid progenitors in normal human long- term bone marrow cultures; compensation by interleukin-3 and granulocyte colony stimulating factor.exp. Hematol.Vol. 21, 1054 (162). 21. Petzer A.L., Geisen F., Bilgeri R., Zilian U.,, Haun M., Herold M, Braunsteiner H., Konwalinka G. (1993) The growth-inhibitory effect of 2-Chloro-2 -deoxyadenosine (CdA) on myeloid progenitors (CFU- GM) in normal human long-term bone marrow cultures can be compensated by the addition of Interleukin-3 (IL-3) or granulocyte colony-stimulating factor (G-CSF). Ann. Hematol., Vol. 67, suppl., Schirmer M, Hilbe W, Geisen F, Fend F, Knoblechner A, Thaler J, Zilian U., Petzer A.L, Konwalinka G. (1994) Monoclonal antibody B-Ly7: Detection of minimal residual disease after treatment of hairy cell leukemia with 2-Chlorodeoxyadenosine. Exp. Hematol.Vol.22, 798 (454). 23. Petzer A, Ponchio L, Ghaffari S, Cashman J, Lansdorp P, Eaves A, Eaves C. (1994) Mobilization of normal LTC-IC in the blood of untreated CML patients with high WBC counts. Blood Vol. 84, No.10, Suppl 1, 400a. 19

20 24. Petzer AL, Lansdorp PM, Hogge DE, Reid D, Eaves CJ. (1995) CD34 ++/ CD38 - cells isolated from normal human marrow can selfrenew and can be extensively amplified in vitro in defined media. J.Hematother. Vol. 4, No. 3, 236 (146). 25. Petzer AL, Lansdorp PM, Shaw G, Barnett MJ, Eaves AC, Eaves CJ. (1995) Elevated numbers od CD38 -, Thy-1 + LTC-IC are present in the blood of newly diagnosed CML patients and include both Ph - and Ph + genotypes. Exp. Hematol.Vol. 23, No. 8, 791 (176). 26. Petzer AL, Lansdorp PM, Hogge DE, Reid D, Eaves CJ. (1995) Extensive amplification of LTC-IC in single cell cultures of normal adult human CD34 ++ /CD38 - marrow cells maintained in defined media. Exp. Hematol. Vol. 23, No. 8, 845 (358). 27. Bockhold K, Petzer A, Eaves C, Hogge D. (1995) Growth factor requirements and phenotypic characterization of human megakaryozyte (Mk) progenitors. Blood Vol. 86, No. 10, suppl 1, 346a (1445). 28. Zandstra PW, Petzer AL, Eaves CJ, Piret JM. (1995) Very high concentrations of cytokines are required for the maximal stimulation in vitro of primitive human hematopoietic progenitors (LTC-IC) and are depleted most rapidly by subpopulations of cells that are highly enriched in their LTC-IC content. Blood Vol. 86, No. 10, suppl 1, 422a (1676). 29. Maguer-Satta V, Petzer A, Ponchio L, Eaves A, Eaves C. (1995) Evidenc eof BCR-ABL gene expression in single CML cells at phenotypically defined and functionally characterized early as well as later stages of hematopoietic cell differentiation. Blood Vol. 86, No. 10, suppl 1, 527a (2095). 20

21 30. Petzer AL, Zandstra PW, Piret JM, Eaves CJ. (1995) The effects of Flk2/Flt3 ligand (FL), Steel factor (SF) and Interleukin 3 (IL-3) are additive and together stimulate an extensive and rapid expansion of primitive cells (LTC-IC) in low density serum-free cultures of CD34 + CD38 - human marrow cells. Blood Vol. 86, No. 10, suppl 1, 493a (1960). 31. Petzer AL, Eaves AC, Eaves CJ. (1995) Rapid loss of the defining attributes of CML LTC-IC in cultures of Ph + CD34 + CD38 - cells maintained in serum-free cytokine-supplemented medium under conditions that stimulate extensive amplification of normal LTC-IC. Blood Vol. 86, No. 10, suppl 1, 601a (2391). 32. Maguer-Satta V, Petzer A, Ponchio L, Eaves A, EavesC (1996) Primitive as well as mature subpopulations of neoplastichematopoietic cells from patients with chronic myeloid leukemia express BCR-ABLmRNA. Brit. J. Haematol, Vol. 93, Suppl 2, 1996, p a. 33. Cashman J, Conneally E, Petzer A, Eaves C. (1996) Characterization of lympho-myeloid stem cells in human cord blood using a quantitative in vivo mouse reconstitution assay. Exp. Hematol.Vol. 24, No. 9, 1035, 66ª. 34. Petzer AL, Eaves AC, Eaves CJ. (1996) Decline of CML (Ph + ) CD34 ++ CD38 - LTC-IC under culture conditions that stimualte expansion of coexisting normal (Ph - ) LTC-IC. Exp.Hematol.Vol. 24, No. 9, 1133, 592a. 21

22 35. Conneally E, Cashman J, Petzer AL, Eaves CJ. (1996) In vitro expansion of human lympho-myeloid stem cells from cord blood demonstrated using a quantitative in vivorepopulating assay. Blood Vol.88, No. 10, Suppl. 1, 628a, (2501). 36. Petzer AL, Zandstra P, Lansdorp PM, Piret J, Eaves CJ. (1996) Significant Expansion of primitive CD34 ++ CD38 - hematopoietic cells (LTC-IC) from human bone marrow in serum-free medium. Acta Med Aust Vol. 23, Sonderheft 1, 1996, Petzer AL, Eaves AC, Eaves CJ. (1996) Establishment of serum-free culture conditions in which CML (Ph + ) CD34 ++ CD38 - LTC-IC decline but coexisting normal (Ph - ) LTC-IC expand. Ann Hematol, Vol. 73, Suppl II, A 96, 382a. Nach der Habilitation: 38. Petzer AL, Eaves AC, Gastl G, Eaves CJ. (1997) Selective Expansion of normal (Ph - ) stem cells (LTC-IC) in cytokinesupplemented cultures from patients with CML. Onkologie, Vol. 20, Sonderheft, p17, 54a. 39. Petzer AL, Eaves AC, Gastl G, Eaves CJ. (1998) In-vitro expansion of normal (Ph - ) stem cells (LTC-IC) in cytokine supplemented cultures from patients with chronic myeloid leukemia. Acta Med. Austriaca, Suppl. 46, 46, p Petzer AL, Gunsilius E, Zech N, Nussbaumer W, Hoflehner E, Gastl G. (1998) Viability cell counts do not predict survival of mature (CFC) and immature progenitor cells (LTC-IC) from apheresis products after overnight storage. Bol. Soc. Bras. Hematol. Hemot. 20 (Suppl). P 30, A

23 41. Petzer AL, Eaves AC, Barnett M, Gastl G, Eaves CJ. (1998) Selective expansion of normal (Ph - ) stem cells (LTC-IC) in chronic myeloid leukemia. Annals of Hematology, Suppl. II to Vol. 77, S 25, Petzer AL, Gunsilius E, Zech N, Clausen J, Hoflehner E, Gastl G. (1999) Evaluation of optimal survival of mature (CFC) and immature progenitor cells (LTC-IC) from apheresis products after overnight (ON) storage. Bone Marrow Transplantation, Vol. 23, Suppl. 1, S 206, Clausen J, Vergeiner B, Petzer AL, Gastl G, Gunsilius E. (1999) Impaired ex-vivo expandability of CD56+ cytotoxic lymphocytes in autologous PBSC transplants from breast cancer patients. Bone MarrowTransplantation, Vol. 23, Suppl. 1, S 25, Gunsilius E, Petzer AL, Stockhammer G, Nussbaumer W, Clausen J, Schumacher P, Gastl G. (1999) Platelets contribute the most to vascular endothelial growth factor levels in peripheral blood. Haematologica, PO Petzer AL, Gunsilius E, Zech N, Clausen J, Hoflehner E, Gastl G. (1999) Evaluation of optimal survival of immature progenitor cells (LTC-IC) from apheresis products under different overnight (ON) storage conditions. Cytotherapie, Vol. 1, No. 3, p217, O Zech N, Gunsilius E, Clausen J, Hoflehner E, Gastl G, Petzer AL (1999) Expansion of apheresed PBPC under clinically applicable conditions. Onkologie 21, suppl. 1,

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA UNFAVORABLE Advanced age High leukocyte count at diagnosis Presence of myeloid antigens Late achievement of CR Chromosomal abnormalities: t(9:22)(q34:q11) t(4;11)(q21;q23)

More information

Stem Cell Transplantation

Stem Cell Transplantation Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each Introduction 1.1 Introduction: About 10,500 new cases of acute myelogenous leukemia are diagnosed each year in the United States (Hope et al., 2003). Acute myelogenous leukemia has several names, including

More information

MEDICAL COVERAGE POLICY

MEDICAL COVERAGE POLICY Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each

More information

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods

More information

Synopsis of Causation. Chronic Myeloid Leukaemia

Synopsis of Causation. Chronic Myeloid Leukaemia Ministry of Defence Synopsis of Causation Chronic Myeloid Leukaemia Author: Dr M A Vickers, University of Aberdeen, Aberdeen Validator: Professor John Goldman, Hammersmith Hospital, London September 2008

More information

Acute myeloid leukemia (AML)

Acute myeloid leukemia (AML) Acute myeloid leukemia (AML) Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult

More information

CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More

CML. cure. A Patient s Guide. Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More A Patient s Guide to CML Molecular Biology Diagnosis Stem Cell Transplant Monitoring New Drugs Questions to Ask and More cure C a n c e r U p d at e s, R e s e a r c h & E d u c at i o n Based on science,

More information

Treating Minimal Residual Disease in Acute Leukemias: How low should you go?

Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Treating Minimal Residual Disease in Acute Leukemias: How low should you go? Ramsie Lujan, Pharm.D. PGY1 Pharmacy Practice Resident Methodist Hospital, San Antonio, Texas Pharmacotherapy Education and

More information

Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2

Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2 Leukaemia: Description A group of malignant disorders affecting: White blood cells (lymphocytes or leucocytes) Bone

More information

in silico hematology

in silico hematology in silico hematology Application of mathematical modeling to predict the outcome of leukemia treatment by Ingmar Glauche and Ingo Röder Chronic Myeloid Leukemia (CML) accounts for about 20 % of all leukemias

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll

More information

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational

More information

Project Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D

Project Lead: Stephen Forman, M.D. PI: Elizabeth Budde, M.D., Ph.D Phase I study using T cells expressing a CD123-specific chimeric antigen receptor and truncated EGFR for patients with relapsed or refractory acute myeloid leukemia Project Lead: Stephen Forman, M.D. PI:

More information

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells

More information

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several

I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several Track 3: Goals of therapy I was just diagnosed, so my doctor and I are deciding on treatment. My doctor said there are several factors she ll use to decide what s best for me. Let s talk about making treatment

More information

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014 ABOUT BLOOD CANCERS Leukemia, Hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) are types of cancer that can affect the

More information

Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation

Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation Dr Ros Ganderton, Ms Kate Parratt, Dr Debbie Richardson, Dr Kim Orchard and Dr Liz Hodges Departments of Molecular Pathology

More information

GRANIX (tbo-filgrastim)

GRANIX (tbo-filgrastim) RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil

More information

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY

CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,

More information

Update in Hematology Oncology Targeted Therapies. Mark Holguin

Update in Hematology Oncology Targeted Therapies. Mark Holguin Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning

More information

Hematologic Malignancies

Hematologic Malignancies Hematologic Malignancies Elizabeth A. Griffiths, MD Leukemia Service, Department of Medicine Roswell Park Cancer Institute SUNY-UB School of Medicine Blood cancers are normal blood cells gone bad Jordan

More information

Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma

Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Acute Lymphoblastic Leukemia (Adult) Including Lymphoblastic lymphoma Updated April 2008 by Dr. Richard Wells* Updates: Minor changes only Introduction Acute lymphocytic leukemia (ALL) is a relatively

More information

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype? Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in

More information

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer

More information

Purification and Expansion of Hematopoietic Stem Cells Based on Proteins Expressed by a Novel Stromal Cell Population

Purification and Expansion of Hematopoietic Stem Cells Based on Proteins Expressed by a Novel Stromal Cell Population Purification and Expansion of Hematopoietic Stem Cells Based on Proteins Expressed by a Novel Stromal Cell Population Our bodies are constantly killing old, nonfunctional, and unneeded cells and making

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

Answering your questions on Chronic Myeloid Leukaemia (CML)

Answering your questions on Chronic Myeloid Leukaemia (CML) Answering your questions on Chronic Myeloid Leukaemia (CML) Your guide to understanding CML and Glivec (imatinib) treatment The information in this booklet is designed to help you understand chronic myeloid

More information

Relative Risk (Sokal & Hasford): Relationship with Treatment Results. Michele Baccarani

Relative Risk (Sokal & Hasford): Relationship with Treatment Results. Michele Baccarani Relative Risk (Sokal & Hasford): Relationship with Treatment Results Michele Baccarani European LeukemiaNet EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA VENICE 8 9 MAY 2006 Disease risk

More information

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers

More information

Stem Cell Transplantation for Acute Lymphoblastic Leukemia

Stem Cell Transplantation for Acute Lymphoblastic Leukemia Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic

More information

The CML Guide Information for Patients and Caregivers

The CML Guide Information for Patients and Caregivers The CML Guide Information for Patients and Caregivers LEUKEMIA LYMPHOMA CHRONIC MYELOGENOUS LEUKEMIA MYELOMA Printing of this publication made possible by a grant from A Message from John Walter President

More information

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,

More information

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, MD Director, Hemotherapy and Stem Cell Processing Facility E-mail: js2745@columbia.edu A 40-year old man with acute myelogenous

More information

Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate

Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate Original Article Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate Joshi S, Sunita P, Deshmukh C, Gujral S, Amre P, Nair CN Department of Pathology,

More information

FastTest. You ve read the book... ... now test yourself

FastTest. You ve read the book... ... now test yourself FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections

More information

Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012

Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012 Arjan A. van de Loosdrecht, MD, PhD Department of Hematology VU University Medical Center VU-Institute of Cancer and Immunology

More information

The use of monoclonal antibodies in the setting of HSCT

The use of monoclonal antibodies in the setting of HSCT The use of monoclonal antibodies in the setting of HSCT S Montoto, Barts Cancer Institute, London, UK Geneva 3/April/2012 www.ebmt.org Some definitions of interest: Ab and Ag Antibody (Ab)=Immunoglobulin

More information

What is a Stem Cell Transplantation?

What is a Stem Cell Transplantation? What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am

More information

Basic Science in Medicine

Basic Science in Medicine Medical Journal of th e Islamic Republic of Iran Volume 18 Number 3 Fall 1383 November 2004 Basic Science in Medicine ] EXPANSION OF HUMAN CORD BLOOD PRIMITIVE PROGENITORS IN SERUM-FREE MEDIA USING HUMAN

More information

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Media Release Basel, 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Approval provides option that improves the length of time people with incurable

More information

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals

What is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application

More information

Proliferation/Potency Assays: Is there more to CD34 and CFU?

Proliferation/Potency Assays: Is there more to CD34 and CFU? Proliferation/Potency Assays: Is there more to CD34 and CFU? CBMTG 2012 Laboratory Committee Meeting April 11, 2012 Toronto, ON, Canada Leah Marquez-Curtis CBS-Edmonton OUTLINE I. Rationale and Definitions

More information

Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies

Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies Myeloid Leukemias - Current and Future Approaches to Targeted and Individualized Therapies Robert J. Arceci, M.D., Ph.D. King Fahd Professor of Pediatric Oncology Professor of Pediatrics, Oncology and

More information

Oncology Best Practice Documentation

Oncology Best Practice Documentation Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings

More information

Cytogenetics for the Rest of Us: A Primer

Cytogenetics for the Rest of Us: A Primer Cytogenetics for the Rest of Us: A Primer James J. Stark, MD, FACP Medical Director Cancer Program Maryview Medical Center Diane Maia, M.D. Pathologist, Bon Secours Hampton Roads Case #1 78 y.o. lady seen

More information

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank Cordblood Stem Cells and The Role of Cordblood Bank in Supporting Stem Cells Research Presentation Overview Company profile Haematopoietic stem cells in cordblood What we can do to help 1 2 PT CordLife

More information

Leukemias and Lymphomas: A primer

Leukemias and Lymphomas: A primer Leukemias and Lymphomas: A primer Normal blood contains circulating white blood cells, red blood cells and platelets 700 red cells (oxygen) 1 white cell Neutrophils (60%) bacterial infection Lymphocytes

More information

Immunophenotyping of Leukemia and Lymphoma. Douaa Moh. Sayed

Immunophenotyping of Leukemia and Lymphoma. Douaa Moh. Sayed Immunophenotyping of Leukemia and Lymphoma By Douaa Moh. Sayed Immunological Classification of Acute leukemia ALL Hybrid AML T-ALL Intermediat T ALL early T-ALL mature T-ALL B-ALL pro-b-all C-ALL pre-b-all

More information

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:

More information

Saving your baby s s cord blood: Is this good insurance?

Saving your baby s s cord blood: Is this good insurance? Saving your baby s s cord blood: Is this good insurance? 32 th SEMINAR ON PERINATAL MEDICINE CONTROVERSIES IN PERINATAL MEDICINE: EVIDENCE FOR CURRENT PRACTICE Sante Fe, New Mexico Mervin C. Yoder, MD

More information

OVERVIEW OF LECTURE CONTENT: INTRODUCTION AND DEFINITIONS OVERVIEW OF THE LYMPHOCYTE + HISTIOCYTE SUBSETS AND THEIR FUNCTIONS OVERVIEW OF NORMAL LYMPH

OVERVIEW OF LECTURE CONTENT: INTRODUCTION AND DEFINITIONS OVERVIEW OF THE LYMPHOCYTE + HISTIOCYTE SUBSETS AND THEIR FUNCTIONS OVERVIEW OF NORMAL LYMPH AN INTRODUCTION TO THE LYMPHOPROLIFERATIVE DISORDERS BY DR Y PERNER DEPARTMENT OF ANATOMICAL PATHOLOGY OVERVIEW OF LECTURE CONTENT: INTRODUCTION AND DEFINITIONS OVERVIEW OF THE LYMPHOCYTE + HISTIOCYTE

More information

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010) MALIGNANT LYMPHOMAS Dr. Olga Vujovic (Updated August 2010) Malignant lymphomas consist of Hodgkin and non-hodgkin lymphomas. The current management of these diseases involves a multi-disciplinary approach.

More information

Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia

Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Dr Jordi Sierra Gil IRHSP Institut de Recerca Hospital de la Santa Creu i Sant Pau Dr. Miguel Ángel Sanz Alonso Fundación

More information

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. TRACEY O CONNOR RESEARCH QUESTON Patients with previously diagnosed hematologic

More information

STEM CELL FELLOWSHIP

STEM CELL FELLOWSHIP Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015 LEUKEMIA Response in Acute Myeloid Leukemia (AML) Response criteria in Acute Myeloid Leukemia for SWOG protocols is based on the review article Diagnosis and management of acute myeloid leukemia in adults:

More information

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

More information

Fresh PBSC harvests, but not BM, show temperature-related loss of CD34 viability during storage and transport

Fresh PBSC harvests, but not BM, show temperature-related loss of CD34 viability during storage and transport Cytotherapy (2006) Vol. 8, No. 2, 158/165 Fresh PBSC harvests, but not BM, show temperature-related loss of CD34 viability during storage and transport V Antonenas 1, F Garvin 1, M Webb 1, M Sartor 2,

More information

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,

More information

The Diagnosis of Myeloid Neoplasia by Flow Cytometry. Brent L. Wood MD PhD Dept. of Laboratory Medicine University of Washington, Seattle

The Diagnosis of Myeloid Neoplasia by Flow Cytometry. Brent L. Wood MD PhD Dept. of Laboratory Medicine University of Washington, Seattle The Diagnosis of Myeloid Neoplasia by Flow Cytometry Brent L. Wood MD PhD Dept. of Laboratory Medicine University of Washington, Seattle Basic Principles Abnormal population identification Normal Antigens

More information

Challenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute

Challenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute Challenges of Hematopoietic Stem Cell Transplantation Robert J. Soiffer, MD Dana Farber Cancer Institute Hematopoietic Stem Cell Transplantation Objectives Deliver sufficient chemo-radio therapy to destroy

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

A disease of populations of cells that live, divide, invade and spread without regard to normal limits

A disease of populations of cells that live, divide, invade and spread without regard to normal limits 1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without

More information

A disease and antibody biology approach to antibody drug discovery

A disease and antibody biology approach to antibody drug discovery A disease and antibody biology approach to antibody drug discovery Björn Frendéus, PhD VP, Preclinical research Presenter: Björn Frendéus Date: 2011-11-08 1 Antibodies have revolutionized Cancer Treatment!

More information

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted

More information

Review. Cord blood as an alternative source of haemopoietic stem cells. J. Hows, A. Nicol, P. Denning-Kendall, C. Donaldson, M. Nieda & B.

Review. Cord blood as an alternative source of haemopoietic stem cells. J. Hows, A. Nicol, P. Denning-Kendall, C. Donaldson, M. Nieda & B. Annals of Oncology 7 (Suppi 2): 47-51, 1996. O 1996 Kluwer Academic Publishers. Printed in the Netherlands. Review Cord blood as an alternative source of haemopoietic stem cells J. Hows, A. Nicol, P. Denning-Kendall,

More information

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points

Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation

More information

CAR T cell therapy for lymphomas

CAR T cell therapy for lymphomas CAR T cell therapy for lymphomas Sattva S. Neelapu, MD Associate Professor and Deputy Chair ad interim Department of Lymphoma and Myeloma UT MD Anderson Cancer Center, Houston, TX CAR T cell therapy What

More information

INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002

INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation

More information

Disclosure. Gene Therapy. Transfer of genes into cells Expression of transferred genes

Disclosure. Gene Therapy. Transfer of genes into cells Expression of transferred genes Disclosure Equity interest in Genetix Pharm. Inc. Exclusive license of retroviral cell lines from Columbia No direct participation in MDR clinical trials Columbia U. annual reporting FDA Gene Therapy Transfer

More information

1 Materials and methods. 1.1 Materials

1 Materials and methods. 1.1 Materials Vol. 44 No. 5 SCIENCE IN CHINA (Series C) October 2001 Expansion of CD34 + cells from human umbilical cord blood by FL and/or TPO gene transfected human marrow stromal cell lines ZHANG Yi (Æ Ê), TANG Peixian

More information

Hematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes

Hematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes Hematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes Asad Bashey, MD, PhD Blood and Marrow Transplantation Program at Northside Hospital Atlanta, Georgia

More information

Blood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide

Blood & Marrow Transplant Glossary. Pediatric Blood and Marrow Transplant Program Patient Guide Blood & Marrow Transplant Glossary Pediatric Blood and Marrow Transplant Program Patient Guide Glossary Absolute Neutrophil Count (ANC) -- Also called "absolute granulocyte count" amount of white blood

More information

Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines

Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival

More information

Shantaram S. Joshi, Ph.D.

Shantaram S. Joshi, Ph.D. Shantaram S. Joshi, Ph.D. Functional Genomics of Leukemia Dendritic Cell Based Therapy for Cancer Dept. of Genetics, Cell Biology and Anatomy University of Nebraska Medical Center Omaha, Nebraska 68198-6395

More information

Stem Cell Transplantation in Adults

Stem Cell Transplantation in Adults Recommendation Report Stem Cell Transplantation in Adults K. Imrie, R.B. Rumble, M. Crump, the Advisory Panel on Bone Marrow and Stem Cell Transplantation, and the Hematology Disease Site Group of Cancer

More information

Developments and Quality Assurance in Stem Cell Transplantation

Developments and Quality Assurance in Stem Cell Transplantation This text is a translation from the original German which should be used for referencing. The German version is authoritative. ORIGINAL ARTICLE Developments and Quality Assurance in Stem Cell Transplantation

More information

Mantle Cell Lymphoma Understanding Your Treatment Options

Mantle Cell Lymphoma Understanding Your Treatment Options New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department

More information

Acute Myeloid Leukemia

Acute Myeloid Leukemia Acute Myeloid Leukemia Introduction Leukemia is cancer of the white blood cells. The increased number of these cells leads to overcrowding of healthy blood cells. As a result, the healthy cells are not

More information

New York Presbyterian Hospital 7/2001-6/2003. Montefiore Medical Center 7/1999-6/2001 Resident, Internal Medicine

New York Presbyterian Hospital 7/2001-6/2003. Montefiore Medical Center 7/1999-6/2001 Resident, Internal Medicine CURRICULUM VITAE 1. Date: April 12, 2013 I. PERSONAL 2. Name: Deborah Zipin Glick, M.D. 3. Office Phone: (954) 698-3639 4. Current Academic Rank: Assistant Professor of Clinical Medicine 5. Primary Department:

More information

Blood-Forming Stem Cell Transplants

Blood-Forming Stem Cell Transplants Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic

More information

Drug Development Services

Drug Development Services Drug Development Services USING BLOOD AND BONE MARROW PRIMARY CELL SYSTEMS Clinically Relevant In Vitro Assays Broad Spectrum of Drug Classes Multi-Species Platforms Enhancing Drug Development through

More information

Acute leukemias and myeloproliferative neoplasms

Acute leukemias and myeloproliferative neoplasms Acute leukemias and myeloproliferative neoplasms GERGELY SZOMBATH SEMMELWEIS UNIVERSITY OF MEDICINE IIIRD. DEPARTMENT OF INTERNAL MEDICINE Basics of acute leukemia Neoplastic disease Cell of origin is

More information

Protocol. Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia

Protocol. Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia Hematopoietic Stem Cell Transplantation for Chronic Myelogenous (80130) Medical Benefit Effective Date: 04/01/13 Next Review Date: 03/16 Preauthorization Yes Review Dates: 04/07, 05/08, 03/10, 03/11, 03/12,

More information

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.

More information

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia

Long Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In

More information

Die Periphere Blutstammzell- Transplantation

Die Periphere Blutstammzell- Transplantation Die Periphere Blutstammzell- Transplantation Martin Körbling DGHO, Stuttgart, Oktober 2012 Der Ursprung des Begriffs Stammzelle Alexander Maximow 1909 A. Maximow, Fol. Haematol. 8;1909:125-134 St. Petersburg

More information

Blood and Marrow Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA

Blood and Marrow Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA Blood and Marrow Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA Table of Contents Introduction 1 Here to Help 2 Normal Blood and Marrow 4 Overview and Types of Stem Cell Transplantation 6 Stem Cell

More information

What is chronic myeloid leukaemia?

What is chronic myeloid leukaemia? Chronic Myeloid Leukaemia What is chronic myeloid leukaemia? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines CHRONIC

More information

Outline of thesis and future perspectives.

Outline of thesis and future perspectives. Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description

More information

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION

More information

Treatment Recommendations for People Living with CML

Treatment Recommendations for People Living with CML Treatment Recommendations for People Living with CML Foreword by CML Workgroup Chronic myeloid leukaemia (CML) is a disease of the blood and bone marrow that results when there is a cancerous transformation

More information

Interesting Case Series. Periorbital Richter Syndrome

Interesting Case Series. Periorbital Richter Syndrome Interesting Case Series Periorbital Richter Syndrome MarkGorman,MRCS,MSc, a Julia Ruston, MRCS, b and Sarath Vennam, BMBS a a Division of Plastic Surgery, Royal Devon and Exeter Hospital, Exeter, Devon,

More information

Blood and Marrow Stem Cell Transplantation

Blood and Marrow Stem Cell Transplantation Blood and Marrow Stem Cell Transplantation Revised 2013 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is committed to

More information

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D.

Chronic Lymphocytic Leukemia. Case Study. AAIM Triennial October 2012 Susan Sokoloski, M.D. Chronic Lymphocytic Leukemia AAIM Triennial October 2012 Susan Sokoloski, M.D. Case Study 57 year old male, trial application for $1,000,000 Universal Life coverage Cover letter from sales agent indicates

More information

Peripheral Blood Stem Cell (PBSC) Collections: Why, What, When. Objectives. Sources of Stem Cells

Peripheral Blood Stem Cell (PBSC) Collections: Why, What, When. Objectives. Sources of Stem Cells Peripheral Blood Stem Cell (PBSC) Collections: Why, What, When Objectives Why do need stem cell transplants What type of cells are we using for stem cell transplants When and how we collect peripheral

More information